Market Trends of Cardiopulmonary Stress Testing Systems Industry
This section covers the major market trends shaping the Cardiopulmonary Stress Testing Systems Market according to our research experts:
Exercise Testing Systems are Expected to Hold the Largest Market Share During the Forecast Period
Exercise testing systems account for a significant share of the market due to their accuracy and the least operating time. The increased preference by physicians and patients due to their cost-effectiveness and multiple applications of these devices also contribute to the rising adoption of these systems, thus fueling the growth of the market.
Exercise cardiac stress testing (EST) is the most widely used cardiac screening test. The patient exercises on a treadmill according to a standardized protocol, with progressive increases in the speed and elevation of the treadmill. During the exercise cardiac stress testing (EST), the patient's electrocardiogram, heart rate, heart rhythm, and blood pressure are continuously monitored.
The positive outcomes of the usage of exercise testing system in early diagnosis of diseases are expected to drive its adoption globally, thus driving the market. For instance, the study from the National Institute of Health, published in June 2022, stated that exercise testing systems are useful for training prescriptions and defining responses to clinical trials. Recent advances in wearable technology and artificial intelligence provide unique opportunities to broaden the application of these tests and facilitate their interpretation. Therefore, with advancements in wearable technologies, the segment is expected to witness strong growth in the coming years.
The presence of multiple exercise testing systems by major players, with multiple advantages and innovations, is expected to boost market growth. For instance, in May 2022, MGC Diagnostics, a global medical technology company, announced that it partnered with UK med-tech company, Bedfont Scientific Ltd, a world leader in breath analysis with a portfolio that includes the NObreath fractional exhaled nitric oxide test monitor for use in the hospital or at remote locations. With such partnerships and activities from key companies, the segment is expected to witness growth during the forecast period.
North America is Expected to Hold a Major Share of the Market
North America is expected to dominate the cardiopulmonary stress testing (CPST) systems market throughout the forecast period. The United States is expected to register significant growth during the forecast period. The dominance is due to the rising prevalence of cardiovascular and pulmonary disorders such as arrhythmia, heart failures, ischemic heart disease, dyspnea, and heart valve imbalance in the United States, generating higher demand for CPST systems.
For instance, according to the May 2022 update by the Centers for Disease Control and Prevention (CDC), the prevalence of obesity was 39.7% in 2021, which is significantly high. Obesity is the major cause of cardiopulmonary diseases, thus driving the market's growth. Increasing incidences of lifestyle diseases and enhanced awareness among medical professionals about the advantages of CPST, along with the availability of advanced healthcare infrastructure in the region, contribute to the segment's outstanding share in the overall revenue.
According to an article published by Indiana University in February 2021, the team launched invasive cardiopulmonary exercise testing, which will allow for invasive hemodynamic assessment of cardiac chambers filling pressure and compliance during exercise. Thus, the availability of such cardiac stress testing in the country may augment the market.
